2. Metabolic Enzyme/Protease
  3. ATP Citrate Lyase
  4. ACLY-IN-4

ACLY-IN-4 是一种 ATP-柠檬酸裂解酶 (ACLY) 抑制剂，其 IC50 为 0.022 μM，Kd 为 0.19 μM。ACLY-IN-4 可结合 ACLY 的变构结合位点。ACLY-IN-4 具有降血脂、抗脂肪变性、改善胰岛素敏感性、抗氧化应激、抗炎和抗纤维化作用。ACLY-IN-4 可缓解肝脂肪变性、全身胰岛素抵抗、氧化应激、肝脏炎症及纤维化。ACLY-IN-4 可用于代谢功能障碍相关脂肪性肝炎的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

ACLY-IN-4

ACLY-IN-4 Chemical Structure

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

ACLY-IN-4 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

ACLY-IN-4 is an ATP-citrate lyase (ACLY) inhibitor with an IC50 of 0.022 μM and a Kd of 0.19 μM. ACLY-IN-4 binds to the allosteric binding site of ACLY. ACLY-IN-4 exhibits hypolipidemic, anti-steatotic, insulin sensitivity-improving, anti-oxidative stress, anti-inflammatory and anti-fibrotic activities. ACLY-IN-4 alleviates hepatic steatosis, systemic insulin resistance, oxidative stress, hepatic inflammation and fibrosis. ACLY-IN-4 can be used for the research of metabolic dysfunction-associated steatohepatitis[1].

体外研究
(In Vitro)

ACLY-IN-4 (Compound C1) (50 μM; 4 h) 可抑制 Oleic acid (HY-N1446) 诱导的 shNC HepG2 细胞脂质蓄积，但该效应在 shACLY HepG2 细胞中被减弱，提示其作用机制依赖于 ACLY[1]。
ACLY-IN-4 (50 μM; 24 h) 可通过依赖 ACLY 的机制下调 Oleic acid 诱导的 shNC HepG2 细胞中脂肪生成相关基因 (FASN、ACC1、SREBP-1c) 的表达[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

ACLY-IN-4 相关抗体:

Real Time qPCR[1]

Cell Line: oleic acid (OA)-induced shNC and shACLY HepG2 cells
Concentration: 50 μM
Incubation Time: 24 h (with 1 mM OA)
Result: Significantly downregulated mRNA expression of FASN, ACC1, and SREBP-1c in OA-induced shNC HepG2 cells.
Abolished the downregulatory effect on mRNA expression of FASN, ACC1, and SREBP-1c in OA-induced shACLY HepG2 cells.
药代动力学
(Parmacokinetics)
Species Dose Route Cmax T1/2 AUCINF_obs CL Bioavailability
Mice[1] 10 mg/kg i.p. 2062 ng/mL 0.42 h 1019 ng·h/mL 413 mL/min/kg 255 %
体内研究
(In Vivo)

ACLY-IN-4 (Compound C1) (10-30 mg/kg；腹腔注射；每日 1 次；持续 8 周) 可显著改善高脂饮食 (HFD) 诱导的小鼠 MASH 模型中的肝脏脂肪变性、全身胰岛素抵抗、氧化应激、炎症及纤维化[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J (male, 8 weeks old, 18-20 g, HFD-induced MASH)[1]
Dosage: 10 mg/kg; 30 mg/kg
Administration: i.p.; daily; 8 weeks
Result: Reduced average body weight to 46.0 g (10 mg/kg) and 32.9 g (vs 49.5 g in HFD control).
Significantly reduced serum triglyceride (TG), total cholesterol (T-CHO), alanine aminotransferase (ALT), aspartate aminotransferase (AST), low-density lipoprotein cholesterol (LDL-C), liver weight, hepatic TG, and hepatic T-CHO at 10 mg/kg.
Restored serum high-density lipoprotein cholesterol (HDL-C) levels at 10 mg/kg.
Significantly reduced hepatic lipid accumulation (confirmed by Oil Red O staining) at 10 mg/kg.
Suppressed hepatic mRNA expression of lipogenic markers (FASN, LXR, SREBP-1c, HMGCR, ACC1, CD36) and pro-inflammatory/fibrotic markers (CD68, TNF-α, NLRP3, ASC, α-SMA) at 10 mg/kg.
Restored mRNA expression of fatty acid oxidation markers (PPARα, CPT1, PPARγ, AMPKα1) at 10 mg/kg.
Reduced hepatic malondialdehyde (MDA) levels at 10 mg/kg.
Reduced liver protein levels of FASN, ACC1, NLRP3, ASC, α-SMA while increasing PPARα levels at 10 mg/kg.
Showed greater reductions in body weight, serum and hepatic lipid parameters, liver weight, and hepatic lipid accumulation than the 10 mg/kg dose at 30 mg/kg.
Produced similar significant effects on gene and protein expression of lipogenic, fatty acid oxidation, inflammatory, and fibrotic markers as the 10 mg/kg dose at 30 mg/kg.
Nearly restored hepatocellular morphology to match the standard diet control group (confirmed by H&E staining) at 30 mg/kg.
分子量

286.24

Formula

C15H10O6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

ACLY-IN-4 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

ACLY-IN-4ATP Citrate LyaseACLYATP-citrate lyaseSREBP-1cmetabolic dysfunction-associated fatty liver diseaseHepG2 cellsmetabolic dysfunction-associated steatohepatitisoleic acidFASNACC1lipogenic geneInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
ACLY-IN-4
目录号：
HY-182751
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z